Pre-earnings options volume in TG Therapeutics is normal with calls leading puts 5:3. Implied volatility suggests the market is anticipating a move near 4.1%, or 65c, after results are released. Median move over the past eight quarters is 8.8%.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
- TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum